Budesonide, Glycopyrrolate, And Formoterol Fumarate

Introduction Overview

Generic Name

budesonide, glycopyrrolate, and formoterol fumarate

Brand Name

Breztri Aerosphere

Dosage Form

Inhalation aerosol for oral inhalation (budesonide 160 mcg, glycopyrrolate 9 mcg, formoterol fumarate 4.8 mcg per inhalation)

Drug Class

Bronchodilator combinations

Pharmacokinetics

Absorption

The components of Breztri Aerosphere—budesonide, glycopyrrolate, and formoterol fumarate—are efficiently absorbed through the respiratory tract following oral inhalation. Budesonide, a corticosteroid, exhibits rapid absorption through lung tissues, with systemic bioavailability affected by first-pass metabolism. Glycopyrrolate, an anticholinergic agent, reaches peak plasma levels within approximately 1 hour after inhalation, reflecting pulmonary absorption. Formoterol fumarate, a long-acting beta2-adrenergic agonist, is absorbed rapidly via the lungs, with onset of action within minutes. The degree of systemic absorption can be influenced by inhalation technique, severity of airway obstruction, and airway inflammation, which may affect drug deposition and clinical response.

Distribution

After absorption, budesonide exhibits high plasma protein binding (~85-90%) and distributes extensively into lung tissues, achieving localized anti-inflammatory effects. Glycopyrrolate shows moderate plasma protein binding (~38%) and is distributed mainly in extracellular fluid compartments; due to its quaternary ammonium structure, it has limited central nervous system penetration. Formoterol is moderately protein-bound (~61-64%) with widespread distribution throughout respiratory smooth muscle and systemic circulation, enabling effective bronchodilation. The distribution volume varies among these drugs but the combination inhaler allows targeted lung delivery with minimal systemic exposure to reduce side effects.

Metabolism

Budesonide undergoes extensive hepatic metabolism primarily via cytochrome P450 3A4 (CYP3A4), resulting in inactive metabolites. Factors affecting CYP3A4 activity, including concomitant medications, may alter budesonide levels. Glycopyrrolate undergoes limited metabolism, with most of the drug excreted unchanged. Formoterol fumarate is metabolized in the liver predominantly through direct conjugation and oxidative metabolism involving CYP enzymes, mainly CYP2D6 and CYP2C9, producing inactive metabolites. Metabolism rates influence the duration and intensity of action of the inhaled agents.

Elimination

Elimination of budesonide occurs mainly via renal excretion of metabolites, with less than 1% excreted unchanged in urine; the elimination half-life is approximately 2 to 3 hours. Glycopyrrolate is primarily eliminated unchanged by renal excretion; its elimination half-life is approximately 13 to 57 hours, depending on patient factors. Formoterol fumarate is eliminated through both renal and fecal routes as inactive metabolites; it has an elimination half-life ranging from 10 to 20 hours, supporting its long-acting bronchodilator activity. Renal or hepatic impairment may affect elimination kinetics necessitating clinical consideration.

Dosage Forms

Adults

Breztri Aerosphere is administered as 2 inhalations (puffs) twice daily using the metered dose inhaler, delivering a fixed dose of budesonide 160 mcg, glycopyrrolate 9 mcg, and formoterol fumarate 4.8 mcg per inhalation. This regimen optimizes symptom control and reduces COPD exacerbations. The inhaler is designed for maintenance therapy in adults with chronic obstructive pulmonary disease (COPD).

Adolescents

Safety and efficacy of Breztri Aerosphere have not been established in adolescent patients; therefore, use in this population is not recommended.

Special Populations

Use in patients with renal or hepatic impairment requires caution, although specific dose adjustments are not established. The medication is contraindicated in pediatric populations due to lack of data. Elderly patients may experience altered pharmacodynamics and require monitoring for side effects. Patients with known hypersensitivity to budesonide, glycopyrrolate, formoterol, or any inhaler component should avoid use. Not recommended during pregnancy or breastfeeding unless benefits outweigh risks; consult healthcare providers. Careful monitoring is advised in patients with osteoporosis, glaucoma, urinary retention, cardiovascular disease, or immunosuppression due to potential exacerbation of these conditions.

Mechanism Of Action

Breztri Aerosphere combines three pharmacologically distinct agents to provide comprehensive management of COPD through synergistic mechanisms.

Budesonide, an inhaled corticosteroid (ICS), exerts potent anti-inflammatory effects by binding to glucocorticoid receptors in airway cells. This receptor-ligand interaction modulates gene expression, downregulating pro-inflammatory cytokines and mediators such as interleukins and tumor necrosis factor-alpha. Consequently, budesonide reduces airway inflammation, edema, mucus production, and hyperresponsiveness, preventing airway remodeling and exacerbations.

Glycopyrrolate, a long-acting muscarinic antagonist (LAMA), inhibits acetylcholine binding at M3 muscarinic receptors on airway smooth muscle. By blocking these receptors, glycopyrrolate prevents cholinergic bronchoconstriction and promotes prolonged bronchodilation by relaxing airway smooth muscles, resulting in widened airways and improved airflow.

Formoterol fumarate, a long-acting beta2-adrenergic receptor agonist (LABA), selectively binds to beta2-adrenergic receptors on bronchial smooth muscle. Activation of these receptors stimulates adenylate cyclase activity, increasing cyclic AMP levels, leading to smooth muscle relaxation and bronchodilation. Formoterol has a rapid onset (within minutes) and prolonged duration of action (≥12 hours), facilitating sustained symptom relief.

Combined, these agents target both the inflammatory and bronchoconstrictive components of COPD, providing enhanced and sustained improvement in pulmonary function compared to monotherapy. Clinical studies demonstrate that the triple combination reduces COPD exacerbations, improves lung function, and enhances patient quality of life. Compared to other combination inhalers, Breztri uniquely combines budesonide with both a LAMA and LABA, broadening the mechanistic coverage of COPD pathophysiology.

Pharmacological Actions

Anti-inflammatory action via inhaled corticosteroid (budesonide) reducing airway inflammation.
Bronchodilation through muscarinic receptor antagonism by glycopyrrolate, preventing cholinergic bronchoconstriction.
Long-acting beta2-adrenergic receptor agonism by formoterol inducing smooth muscle relaxation.
Reduction of COPD symptom frequency and severity by addressing multiple pathophysiologic mechanisms simultaneously.
Improvement in airflow and lung function through additive pharmacologic effects.
Prevention of airway remodeling through suppression of pro-inflammatory mediators.
Sustained bronchodilation maintained over 12 hours to facilitate twice-daily dosing.
Immunomodulatory effects decreasing exacerbation rates and improving respiratory health.

Therapeutic Clinical Uses

Maintenance treatment of chronic obstructive pulmonary disease (COPD) in adults.
Management of airflow obstruction and symptoms in patients with chronic bronchitis or emphysema.
Reduction in frequency of COPD exacerbations and flare-ups.
Improvement of lung function and respiratory symptoms including dyspnea and chronic cough.
Not indicated for relief of acute bronchospasm or sudden breathing problems.
Supportive therapy to reduce hospitalizations and improve quality of life in COPD.
Treatment option for patients inadequately controlled on dual bronchodilator or ICS/LABA therapy.
Alternative triple therapy in COPD patients requiring combined anti-inflammatory and bronchodilator agents.

Side Or Adverse Effects

Upper respiratory tract infections including nasopharyngitis.
Pneumonia, particularly in COPD patients, potentially linked to ICS use.
Oropharyngeal candidiasis (thrush) due to local immunosuppression; oral rinsing recommended.
Back pain and musculoskeletal discomfort.
Joint pain and muscle spasms (myalgia).
Headache and flu-like symptoms.
Cough and sinus inflammation (sinusitis).
Gastrointestinal disturbances including diarrhea and nausea.
Hoarseness and dysphonia from corticosteroid inhalation.
Elevation of blood glucose levels (hyperglycemia).
Urinary tract infections presenting as painful and frequent urination.
Sleep disturbances including insomnia.
Palpitations, tachycardia, or cardiac arrhythmias.
Anxiety, nervousness, and tremors.
Potential bone thinning or osteoporosis with prolonged ICS use.

Precautions

Rinse mouth after inhalation to reduce risk of oral thrush.
Monitor for signs of pneumonia in COPD patients.
Use cautiously in patients with existing heart disease or arrhythmias.
Avoid abrupt discontinuation in patients tapering from systemic corticosteroids to prevent adrenal insufficiency.
Be vigilant for potential worsening of glaucoma or cataracts.
Avoid use in patients with urinary retention or prostatic hyperplasia without careful evaluation.
Regularly monitor blood glucose in diabetic patients due to possible hyperglycemia.
Avoid concomitant use of other LABA or anticholinergic inhalers to prevent additive effects.
Monitor potassium levels as hypokalemia can occur, increasing risk of cardiac complications.
Assess bone mineral density periodically if used long term due to osteoporosis risk.
Inform patients about not using Breztri for acute bronchospasm; ensure rescue inhaler availability.
Evaluate immunosuppression risks, especially with concurrent infections or immunosuppressive therapies.
Be alert for paradoxical bronchospasm; discontinue if it occurs.
Caution in patients with thyroid disorders or seizure disorders.
Evaluate elderly patients carefully due to increased susceptibility to side effects.

Warnings

Risk of serious fungal infections in mouth and throat; oral hygiene required.
Increased risk of pneumonia in COPD patients treated with inhaled corticosteroids.
Potential for adrenal insufficiency during corticosteroid transitions or stress conditions.
Possible sudden worsening of breathing immediately after inhaler use; stop and seek medical attention.
Serious allergic reactions including rash, hives, angioedema, respiratory distress.
Potential cardiovascular effects including hypertension, tachycardia, palpitations, and arrhythmias.
Nervous system effects such as tremor, anxiety, and nervousness.
Bone density reduction and increased fracture risk with long-term use.
Possibility of acute narrow-angle glaucoma and cataract formation.
Risk of urinary retention and related urinary symptoms.
Changes in laboratory values including elevated blood sugar and decreased potassium.
Not approved for pediatric use; safety and efficacy not established.
Avoid exposure to chickenpox or measles due to immunosuppressive effects.
Not suitable as rescue treatment for acute COPD symptoms.

Contraindications

Known hypersensitivity to budesonide, glycopyrrolate, formoterol fumarate, or any inhaler constituents.
Primary treatment of asthma as safety and efficacy have not been established.
Use with concurrent LABA or LAMA-containing inhalers to avoid overdose and side effects.
Patients with severe hypersensitivity reactions to corticosteroids or anticholinergics.
Situations requiring immediate relief of acute bronchospasm (use rescue inhalers instead).
Patients with untreated active infections due to potential immunosuppression.
Known hypersensitivity to hydrofluoroalkane propellants or porous particle components.
Use in pediatric patients is contraindicated due to lack of established safety.
Concurrent use with other triple combination inhalers like Trelegy.

Drug Interactions

Concomitant use with other anticholinergic drugs (e.g., tiotropium, ipratropium) may increase anticholinergic effects.
Other LABA-containing medications (e.g., salmeterol, vilanterol) can enhance beta2-adrenergic effects increasing side effect risk.
Atropine and other antimuscarinic agents may potentiate bronchodilator and systemic anticholinergic effects.
Antifungal agents (e.g., ketoconazole) and anti-HIV protease inhibitors may elevate budesonide plasma levels by inhibiting CYP3A4 metabolism.
Beta-blockers, including eye drops, may antagonize formoterol effects, reducing bronchodilation.
Diuretics, corticosteroids, or laxatives can exacerbate hypokalemia risk when used with formoterol.
Monoamine oxidase inhibitors (MAOIs) and tricyclic antidepressants may potentiate cardiovascular side effects of formoterol.
Use with other immunosuppressive therapies may enhance immunosuppression risk.
Systemic corticosteroids tapering requires monitoring to avoid adrenal insufficiency when starting Breztri.
Caution with other drugs affecting heart rate or blood pressure due to possible additive cardiovascular effects.

Preparations Of The Drug

Metered dose inhaler (aerosol) delivering budesonide 160 mcg, glycopyrrolate 9 mcg, formoterol fumarate 4.8 mcg per actuation.
Available in canisters containing either 28 or 120 inhalations.
Inhaler utilizes hydrofluoroalkane (HFA 134a) propellant with porous DSPC and calcium chloride particles for consistent aerosolization.
Packaged with a mouthpiece and dose counter to track remaining inhalations.
Comes in foil pouches unopened for protection from moisture and contamination.
Do not use after 3 months from foil pouch opening or when dose counter reaches zero.
Designed for twice-daily administration by oral inhalation.
No generic equivalents currently available; marketed by AstraZeneca.